Applied DNA Sciences Rebrands as BNB-Focused Digital Asset Company, Partners with B2i Digital
Applied DNA Sciences is undergoing a strategic transformation from nucleic acid manufacturing to a BNB-focused digital asset treasury strategy while partnering with B2i Digital to reach over 1.4 million investors through its multi-channel network.
Applied DNA Sciences, Inc. (NASDAQ: BNBX) has been named a B2i Digital Featured Company as it completes a strategic rebrand reflecting its shift toward a yield-focused BNB digital asset treasury strategy. The biotechnology company, which previously focused on nucleic acid production solutions, is now positioning itself as a digital asset management firm while maintaining its core technology platform.
The company's transformation includes approximately $27 million in aggregate gross proceeds to implement its BNB treasury strategy, managed under five-year agreements with Cypress LLC and Cypress Management LLC. This strategic pivot was further emphasized by the company's ticker symbol change from "APDN" to "BNBX" effective October 7, 2025, signaling its commitment to digital asset integration.
David Shapiro, CEO of B2i Digital, stated that Applied DNA's shift toward a BNB-centric digital asset treasury underscores its commitment to innovation in corporate finance and shareholder alignment. The partnership will leverage B2i Digital's extensive investor network of over 1.4 million market participants across multiple platforms including LinkedIn, X, and Facebook.
Clay Shorrock, CEO of Applied DNA Sciences, emphasized that the collaboration with B2i Digital will help communicate the company's transformation and long-term vision to a broader investor audience. The company believes its approach to digital asset management supports both growth initiatives and balance-sheet strength while generating yield and token accumulation within the Binance ecosystem.
Despite the strategic shift toward digital assets, Applied DNA continues to commercialize nucleic acid production technologies through its LineaRx subsidiary. The company maintains its LineaDNA™, LineaRNAP™, and LineaIVT™ platforms, which enable cell-free manufacturing of DNA and RNA for therapeutics and diagnostics markets.
As a B2i Digital Featured Company, Applied DNA will benefit from dedicated digital content, investor presentations, and company updates distributed across B2i Digital's multi-channel network, which also includes Instagram, YouTube, and Stocktwits. This comprehensive digital marketing approach is designed to highlight Applied DNA's strategic transformation and communicate its evolving growth narrative at scale to both retail and institutional investors.
The company's dual approach represents a significant evolution in corporate strategy, combining traditional biotechnology expertise with emerging digital asset management capabilities. This transformation reflects broader trends in corporate finance where companies are increasingly exploring digital asset integration as part of treasury management and value creation strategies.